Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
38 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Pieris AG - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Pieris AG - Product Pipeline Review - 2014', provides an overview of the Pieris AG's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Pieris AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Pieris AG including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Pieris AG's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Pieris AG's pipeline products Reasons to buy - Evaluate Pieris AG's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Pieris AG in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Pieris AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Pieris AG and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pieris AG - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Pieris AG and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Pieris AG Snapshot 5 Pieris AG Overview 5 Key Information 5 Key Facts 5 Pieris AG - Research and Development Overview 6 Key Therapeutic Areas 6 Pieris AG - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Out-Licensed Products 11 Out-Licensed Products/Combination Treatment Modalities 12 Pieris AG - Pipeline Products Glance 13 Pieris AG - Clinical Stage Pipeline Products 13 Phase I Products/Combination Treatment Modalities 13 Pieris AG - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Discovery Products/Combination Treatment Modalities 15 Pieris AG - Drug Profiles 16 PRS-050 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 PRS-080 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 PRS-060 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 PRS-110 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 PRS-NN 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Recombinant Protein 1 for Undisclosed Indication 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Recombinant Protein 2 for Undisclosed Indication 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Recombinant Proteins for Imuunology and Cancer 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Recombinant Proteins for Undisclosed Indication 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 PRS-190 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Recombinant Protein for Ophthalmology 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Recombinant Proteins 3 for Undisclosed Indication 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Recombinant Proteins for Immuno-Oncology Diseases 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Pieris AG - Pipeline Analysis 29 Pieris AG - Pipeline Products by Target 29 Pieris AG - Pipeline Products by Route of Administration 30 Pieris AG - Pipeline Products by Molecule Type 31 Pieris AG - Pipeline Products by Mechanism of Action 32 Pieris AG - Recent Pipeline Updates 33 Pieris AG - Dormant Projects 35 Pieris AG - Locations And Subsidiaries 36 Head Office 36 Appendix 37 Methodology 37 Coverage 37 Secondary Research 37 Primary Research 37 Expert Panel Validation 37 Contact Us 38 Disclaimer 38
List of Tables Pieris AG, Key Information 5 Pieris AG, Key Facts 5 Pieris AG - Pipeline by Indication, 2014 8 Pieris AG - Pipeline by Stage of Development, 2014 9 Pieris AG - Monotherapy Products in Pipeline, 2014 10 Pieris AG - Out-Licensed Products in Pipeline, 2014 11 Pieris AG - Out-Licensed Products/ Combination Treatment Modalities, 2014 12 Pieris AG - Phase I, 2014 13 Pieris AG - Preclinical, 2014 14 Pieris AG - Discovery, 2014 15 Pieris AG - Pipeline by Target, 2014 29 Pieris AG - Pipeline by Route of Administration, 2014 30 Pieris AG - Pipeline by Molecule Type, 2014 31 Pieris AG - Pipeline Products by Mechanism of Action, 2014 32 Pieris AG - Recent Pipeline Updates, 2014 33 Pieris AG - Dormant Developmental Projects,2014 35
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.